Monday, September 17, 2018 -- While AstraZeneca touted Lumoxiti as the first new therapy for HCL in 20 years, a leukemia expert downplayed the significance of the trial data that led to the approval.
Thursday, September 20, 2018 -- Despite continued progress in drug development for acute leukemias, outcomes for patients with some subtypes have not changed significantly in the last decade. Recurrent chromosomal translocations have long been recognized as driver events in leukemia, and many of these oncogenic fusions portend high-risk disease. Improved understanding of the molecular underpinnings of these fusions, coupled with novel chemistry approaches, now provide new opportunity for therapeutic inroads into the treatment of leukemia driven by these fusions.
Thursday, September 20, 2018 -- Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Tuesday, September 18, 2018 -- NewsThe U.S. Food and Drug Administration approved Lumoxiti injection for intravenous use for the treatment of adult patients with hairy cell leukemia.Contributed Author: FDATopics: Orphan Drugs